- Conditions
- Pulmonary Hypertension Due to Left Heart Disease
- Interventions
- Treprostinil Diolamine
- Drug
- Lead sponsor
- Mardi Gomberg -Maitland MD, MSc
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Columbus, Ohio • Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 30
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pulmonary Hypertension
- Interventions
- BQ-123
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1999 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pulmonary Hypertension, Pulmonary Hypertension Due to Lung Diseases
- Interventions
- Pioglitazone 30mg, Placebo, Labs
- Drug · Diagnostic Test
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
- Interventions
- Cannabis, Medical, RYAH-Medtech Inhaler
- Drug · Device
- Lead sponsor
- OMNI Medical Services, LLC
- Network
- Eligibility
- 7 Years and older
- Enrollment
- 200,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2025
- U.S. locations
- 17
- States / cities
- Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
- Conditions
- Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
- Interventions
- Prospective study assessments
- Other
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 70
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more
- Conditions
- Pulmonary Hypertension Due to Lung Diseases and Hypoxia
- Interventions
- Placebo, LAM-001
- Drug
- Lead sponsor
- IRulya Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 24 more
- Conditions
- Heart Diseases, Hypertension, Pulmonary
- Interventions
- tezosentan, placebo
- Drug
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 9
- States / cities
- Stanford, California • New York, New York • Durham, North Carolina + 5 more
- Conditions
- Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute, Myocarditis Due to Drug, Myocarditis Viral, Pericardial Diseases, Valvular Heart Diseases, Hypertension, Sepsis, Acute Kidney Injury, Pulmonary Edema - Acute, Pulmonary Edema With Heart Failure, Pulmonary Edemas, Acute Respiratory Distress Syndrome, Pulmonary Embolism Acute, Pulmonary Embolism (Diagnosis), Pulmonary Embolism Acute Massive, Pulmonary Embolism Subacute Massive, Venous Thrombosis Pulmonary, Venous Thrombosis (Disorder), Venous Thrombosis, Deep, Peripheral Arterial Disease, Peripheral Arterial Disease (PAD), Aortic Diseases, Muskuloskeletal Diseases, Brain Aging, Brain Aneurysm, Brain Aging Related Conditions, Ultrasound, Ultrasound Exams, Ultrasound Guidance
- Interventions
- OMNIPHYS Multimodal Ultrasound Imaging System
- Device
- Lead sponsor
- Truway Health, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2046
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pulmonary Hypertension Due to Lung Disease (Disorder)
- Interventions
- L606, Placebo
- Drug
- Lead sponsor
- Liquidia Technologies, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 9 more
- Conditions
- Pulmonary Hypertension
- Interventions
- Macitentan, Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 6
- States / cities
- Louisville, Kentucky • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
- Conditions
- Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Bronchopulmonary Dysplasia
- Interventions
- GlucoCorticoid
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 1 Day to 5 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
- Interventions
- Inhaled Treprostinil, Placebo
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 96
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 71 more
- Conditions
- Hypertension, Pulmonary
- Interventions
- Sotatercept 0.3 mg/kg, Placebo, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
- Drug
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 56
- States / cities
- Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 46 more
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Lung Diseases
- Interventions
- L606 inhalation suspension
- Combination Product
- Lead sponsor
- Liquidia Technologies, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 5 more
- Conditions
- Bronchopulmonary Dysplasia, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Extreme Prematurity, Ventilator Lung; Newborn, Ventilation Perfusion Mismatch
- Interventions
- Increase in the PEEP followed by decrease in the PEEP, Decrease in the PEEP followed by increase in the PEEP
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 7 Days to 30 Days
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Angina, Pulmonary Arterial Hypertension
- Interventions
- Ranolazine
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Heart Failure, Pulmonary Hypertension
- Interventions
- Rivet Shunt
- Device
- Lead sponsor
- NXT Biomedical
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Rochester, Minnesota • Charlottesville, Virginia
- Conditions
- Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Tadalafil, placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 5
- States / cities
- West Los Angeles, California • Denver, Colorado • Decatur, Georgia + 2 more
- Conditions
- Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction, Hypertension, Vascular Diseases, Cardiovascular Diseases, Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
- Interventions
- Pulmonary Artery Denervation (PADN), Sham procedure control
- Device
- Lead sponsor
- Pulnovo Medical, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 12
- States / cities
- Tucson, Arizona • New Haven, Connecticut • Weston, Florida + 8 more
- Conditions
- Hypertension, Pulmonary, Lung Diseases, Interstitial
- Interventions
- TX000045
- Drug
- Lead sponsor
- Tectonic Operating Company, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • San Francisco, California • Idaho Falls, Idaho + 1 more
- Conditions
- Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
- Interventions
- Inhaled treprostinil solution, Placebo solution
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
- Conditions
- Hypotension and Shock, Pulmonary Hypertension of the Newborn (PPHN), Hypoxemic Respiratory Failure
- Interventions
- Dopamine administration, Norepinephrine
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- Up to 28 Days
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
- Interventions
- AZD3427, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- Beverly Hills, California • La Jolla, California • New Haven, Connecticut + 4 more
- Conditions
- Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
- Interventions
- Inhaled treprostinil solution
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Sacramento, California • Clearwater, Florida + 23 more